Optimal Courses of Chemotherapy Combined with Radiotherapy for Low-Risk Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Propensity Score Matching Analysis

被引:1
|
作者
Li, Jin [1 ]
Li, Yajun [2 ]
Zeng, Ruolan [2 ]
Lin, Jingguan [1 ]
Zhong, Meizuo [3 ]
Liu, Xianling [4 ]
He, Yizi [2 ]
He, Junqiao [2 ]
Ouyang, Zhou [2 ]
Huang, Lijun [2 ]
Xiao, Ling [5 ]
Zhou, Hui [2 ]
机构
[1] Hunan Canc Hosp, Dept Comprehens Chemotherapy Daytime Chemotherapy, Changsha, Hunan, Peoples R China
[2] Hunan Canc Hosp, Dept Lymphoma & Hematol, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Sch Basic Med Sci, Dept Histol & Embryol, Changsha, Hunan, Peoples R China
关键词
extranodal natural killer/T-cell lymphoma; nasal type; chemotherapy courses; low-risk; L-ASPARAGINASE; T-CELL; STAGE IE; CONCURRENT CHEMORADIOTHERAPY; RADIATION-THERAPY; GEMCITABINE; ETOPOSIDE; IIE; DEXAMETHASONE; MULTICENTER;
D O I
10.2147/TCRM.S254246
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose: This retrospective study compared effectiveness between <= 4 cycles and >= 5 cycles of L-asparaginase/pegaspargase-based chemoradiation in newly diagnosed low-risk extranodal natural killer/T-cell lymphoma (ENKTL), nasal type classified according to the Prognostic Index of Natural Killer (PINK) lymphoma model. Patients and Methods: Patients were categorized into <= 4-cycle (2-4 chemotherapy cycles, n = 166) and >= 5-cycle groups (5-6 cycles, n = 86). Propensity score matching analysis was used to reduce potential confounding bias between the two groups. Treatment responses, adverse events, and survival outcomes between the two groups were analyzed. Results: No matter before or after matching (65 in the <= 4-cycle group, 65 in the >= 5-cycle group), response rates and survival outcomes were similar between the <= 4-cycle and >= 5-cycle groups. Incidences of grade 1-2 anemia and transaminase elevation were higher in the >= 5-cycle group. After matching, for stage IE disease, there were no differences in response rates and survival outcomes between the two groups. For stage IIE disease, the complete response rate was higher in the >= 5-cycle group (72.4% vs 92.6%, p = 0.049), and the 3-year overall survival (65.5% vs 85.2%, p = 0.024) and 3-year progression-free survival (58.6% vs 81.5%, p = 0.027) rates were significantly extended in the >= 5-cycle group. Conclusion: When chemoradiotherapy strategies with L-asparaginase/pegaspargase-based regimens are applied to modem low-risk ENKTL patients classified according to the PINK model, it may be better to moderately extend chemotherapy courses in patients with stage IIE disease.
引用
收藏
页码:1151 / 1163
页数:13
相关论文
共 50 条
  • [1] Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma
    Luo, Jialin
    Cao, Caineng
    Zhu, Yuan
    Liu, Peng
    Liu, Luying
    Lu, Ke
    Zhang, Na
    Zhou, Ning
    ONCOTARGETS AND THERAPY, 2016, 9 : 6147 - 6150
  • [2] Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment
    van Doesum, Jaap A.
    Niezink, Anne G. H.
    Huls, Gerwin A.
    Beijert, Max
    Diepstra, Arjan
    van Meerten, Tom
    HEMASPHERE, 2021, 5 (02):
  • [3] Management of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    Chaudhary, Ranjit Kumar
    Bhatt, Vijaya Raj
    Vose, Julie M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (05) : 245 - 252
  • [4] Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis
    Wei, Liqiang
    Wang, Liang
    Cong, Jia
    Yang, Lei
    Ye, Jin
    Li, Xin
    Yao, Na
    Yang, Jing
    Cui, Xueying
    Wu, Yiping
    Ding, Jing
    Wang, Jingwen
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2962 - 2968
  • [5] Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type
    Tian, Shu
    Li, Ruichen
    Wang, Tian
    Wang, Shengzi
    Tao, Rong
    Hu, Xichun
    Ding, Hao
    CANCER MEDICINE, 2019, 8 (07): : 3349 - 3358
  • [6] Efficacy of Frontline Chemotherapy for Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Network Meta-Analysis
    Luo, Fei
    Wang, Jing Nan
    Liu, Xin
    Wang, Xin
    Qi, Shu Nan
    Li, Ye Xiong
    JOURNAL OF HEMATOLOGY, 2023, 12 (05) : 215 - 226
  • [7] Incidence and treatment of extranodal natural killer/T-cell lymphoma, nasal type. Hungarian experiences
    Annamaria, Bakos
    Arpad, Szomor
    Tamas, Schneider
    Zsofia, Miltenyi
    Imelda, Marton
    Zita, Borbenyi
    Judit, Pammer
    Laszlo, Krenacs
    Eniko, Bagdi
    Klara, Piukovics
    ORVOSI HETILAP, 2017, 158 (41) : 1635 - 1641
  • [8] Conjunctival Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
    Kiratli, Hayyam
    Uzun, Salih
    Yesilirmak, Aysun
    Ayhan, Arzu Saglam
    Soylemezoglu, Figen
    CORNEA, 2015, 34 (06) : 710 - 712
  • [9] Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
    Wang, Hua
    Li, Pengfei
    Zhang, Xinke
    Xia, Zhongjun
    Lu, Yue
    Huang, Huiqiang
    ONCOLOGY LETTERS, 2016, 12 (02) : 825 - 836
  • [10] Body mass index as a prognostic factor in patients with extranodal natural killer/T-cell lymphoma, nasal type
    Liu, Jie
    Deng, Yao-Tiao
    Zhang, Li
    Li, Na
    Jiang, Ming
    Zou, Li-Qun
    Jiang, Yu
    ONCOTARGET, 2016, 7 (47) : 78159 - 78167